CDKN2A and neoplasm: The senescence marker p16 can serve as an early tumor-suppressive and senescence indicator during esophageal epithelial progression, but its epigenetic inactivation (e.g., promoter methylation) or therapy-induced re-expression is also associated with tumorigenesis (Domen et al., 2022).